XML 61 R50.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
segment
Sep. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Segment Information          
Number of reportable segments | segment     2    
Accumulated deficit $ 947,989   $ 947,989   $ 902,861
Total revenue 3,299 $ 4,346 6,531 $ 9,509  
Total research and development 13,028 5,956 36,061 24,560  
General and administrative 4,871 5,653 16,396 17,249  
Licensing 1,911 1,754 4,256 4,070  
Revaluation of contingent consideration 100 800 1,900 3,800  
Segment operating loss (17,149) (10,471) (53,641) (42,257)  
Other income 2,535 2,885 8,513 6,744  
Loss before income taxes (14,614) (7,586) (45,128) (35,513)  
Operating Segments | Therapeutics Segment          
Segment Information          
Total revenue 2,814 3,701 5,159 7,583  
Total research and development project expenses 8,708 2,008 22,868 5,968  
Personnel 2,993 1,970 8,904 9,002  
Other research and development expense 1,541 2,182 4,950 10,241  
Total research and development 13,242 6,160 36,722 25,211  
Licensing 1,911 1,754 4,256 4,070  
Revaluation of contingent consideration 100 800 1,900 3,800  
Segment operating loss (12,439) (5,013) (37,719) (25,498)  
Operating Segments | Contract Research Segment          
Segment Information          
Total revenue 485 645 1,372 1,926  
Cost of revenue 4,454 3,485 11,983 11,558  
General and administrative 467 905 1,989 3,033  
Segment operating loss (306) (710) (1,515) (2,543)  
Operating Segments | Bosakitug | Therapeutics Segment          
Segment Information          
Total research and development project expenses 3,062   9,293    
Operating Segments | ATI-2138 | Therapeutics Segment          
Segment Information          
Total research and development project expenses 1,469 745 4,395 1,560  
Operating Segments | ATI-052 | Therapeutics Segment          
Segment Information          
Total research and development project expenses 1,837   3,874    
Operating Segments | Discovery | Therapeutics Segment          
Segment Information          
Total research and development project expenses 2,340 1,263 5,306 4,408  
Intersegment Eliminations          
Segment Information          
Total revenue (4,130) (3,035) (11,085) (10,122)  
Cost of revenue (3,916) (2,831) (10,424) (9,471)  
Total research and development (214) (204) (661) (651)  
Intersegment Eliminations | Contract Research Segment          
Segment Information          
Total revenue 4,130 3,035 11,085 10,122  
Total          
Segment Information          
Total revenue 3,299 4,346 6,531 9,509  
Cost of revenue 538 654 1,559 2,087  
Total research and development project expenses 8,708 2,008 22,868 5,968  
Personnel 2,993 1,970 8,904 9,002  
Other research and development expense 1,541 2,182 4,950 10,241  
Total research and development 13,028 5,956 36,061 24,560  
General and administrative 467 905 1,989 3,033  
Licensing 1,911 1,754 4,256 4,070  
Revaluation of contingent consideration 100 800 1,900 3,800  
Segment operating loss (12,745) (5,723) (39,234) (28,041)  
Total | Bosakitug          
Segment Information          
Total research and development project expenses 3,062   9,293    
Total | ATI-2138          
Segment Information          
Total research and development project expenses 1,469 745 4,395 1,560  
Total | ATI-052          
Segment Information          
Total research and development project expenses 1,837   3,874    
Total | Discovery          
Segment Information          
Total research and development project expenses 2,340 1,263 5,306 4,408  
Reconciliation of segment          
Segment Information          
General and administrative 4,404 4,748 14,407 14,216  
Other income $ 2,535 $ 2,885 $ 8,513 $ 6,744